Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > This game isn’t over $$$
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(345)
•••
Comment by Qtrlbderon Apr 01, 2021 12:42am
279 Views
Post# 32920661

RE:RE:This game isn’t over $$$

RE:RE:This game isn’t over $$$That's right! IMHO, the top line data is showing good results thus far. What happened today is "sell on the news" and weak hand usually get flush out. I am holding on to my shares and gonna wait until the final data is release.
Mole101 wrote:
 
@Hasetohru
 
Exactly as we expected the power of Ifenprodil to COVID-19 toxicity, Ifenprodil is a real silver power for our human lives.





Mole101 wrote:

 
 
 
 
 
@Hasetohru
 
Exactly as we expected the power of Ifenprodil to COVID-19 toxicity, Ifenprodil is a real silver power for our human lives.
Quote Tweet
Algernon Pharmaceuticals
 
@AlgernonPharma
·
NEWS RELEASE: We are pleased to announce topline data from the Phase 2b part of our Phase 2b/3 #COVID-19 trial of Ifenprodil. We look forward to completing our final data review and receiving feedback from the @US_FDA. Details: bit.ly/3rzo9yl





<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities